期刊文献+

脂毒性与非酒精性脂肪肝的研究进展 被引量:5

Advances of Research on Lipotoxicity and Nonalcoholic Fatty Liver Disease
原文传递
导出
摘要 非酒精性脂肪肝(NAFLD)的病理与脂毒性密切相关。血中游离脂肪酸(freefatty acid,FFA)水平过高,瘦素代偿调节脂质氧化功能失调,造成FFA沉积在肝脏,导致肝细胞脂毒性,发生脂性凋亡。其凋亡机制主要与线粒体、溶酶体、Fas及内质网应激有关。降低血中FFA浓度,减少FFA在肝细胞的沉积,增加FFA的氧化能防止脂毒性的发生。开发改变脂肪酸代谢,降低脂毒性的药物将有很大的应用前景。 Objective:Lipotoxicity is crucial to the pathogenesis of nonalcoholic fatty liver disease(NAFLD).If liver is exposed to an excess of free fatty acids in blood,unless leptin action increases their oxidation sufficiently,unoxidized fatty acids will deposit in hepatocytes and cause lipotoxicity and lipoapoptosis.The mechanisms of this programmed cell death involve mitochondrion and lysosomes dysfunction,Fas expression and endoplasmic reticulum(ER)stress.The measures to prevent lipotoxicity include decreasing l...
出处 《华西医学》 CAS 2008年第6期1482-1484,共3页 West China Medical Journal
关键词 游离脂肪酸 脂毒性 非酒精性脂肪肝 free fatty acids lipotoxicity nonalcoholic fatty liver disease
  • 相关文献

参考文献25

  • 1[1]Feldstein AE,Gores GJ.Apoptosis in alcoholic and nonalcoholic steatohepatitis[J].Front Biosci,2005,10:3093-3099. 被引量:1
  • 2[2]McCullough AJ.The clinical features,diagnosis and natural history of nonalcoholic fatty liver disease[J].Clin Liver Dis,2004,8(3):521-533,ⅷ. 被引量:1
  • 3[3]Unger RH.Lipid overload and overflow:metabolic trauma and the metabolic syndrome[J].Trends Endocrinol Metab,2003,14(9):398-403. 被引量:1
  • 4[4]Lee Y,Hirose H,Ohneda M,et al.Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats:impairment in adipocyte-β-cell relationships[J].Proc Natl Acad Sci U S A,1994,91(23):10878-10882. 被引量:1
  • 5[5]Browning JD,Horton JD.Molecular mediators of hepatic steatosis and liver injury[J].J Clin Invest,2004,114(2):147-152. 被引量:1
  • 6[6]Chinen I,Shimabukuro M,Yamakawa K,et al.Vascular lipotoxicity:endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats[J].Endocrinology,2007,148(1):160-165.Erratum in:Endocrinology,2007,148(5):2055. 被引量:1
  • 7[7]Unger RH,Orci L.Lipoapoptosis:its mechanism and its diseases[J].Biochim Biophys Acta,2002,1585(2-3):2 02-212. 被引量:1
  • 8[8]Unger RH,Orci L.Diseases of liporegulation:new perspective on obesity and related disorders[J].FASEB J,2001,15(2):312-321. 被引量:1
  • 9[9]sidine RV,Sinha MK,Heiman ML,et al.Serum immunoreactive-leptin concentrations in normal-weight and obese humans[J].N Engl J Med,1996,334(5):292-295. 被引量:1
  • 10[10]Gómez-Lechón MJ,Donato MT,Martínez-Romero A,et al.A human hepatocellular in vitro model to investigate steatosis[J].Chem Biol Interact,2007,165(2):106-116. 被引量:1

同被引文献44

  • 1杨玉芝,冯琨,王丹,朱巍.罗格列酮独特的作用机理及其在2型糖尿病理性化治疗中的应用[J].实用糖尿病杂志,2005,13(1):10-12. 被引量:10
  • 2Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量:1515
  • 3陈家伦.噻唑烷二酮类.见:许曼音主编:糖尿病学.上海科学技术出版社,2003.338-346. 被引量:2
  • 4Targher G, Bertolini L, Padovani R, et al. Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease[J]. Diabet Med, 2006, 23(4): 403-409. 被引量:1
  • 5Targher G, Bertolini L, Padovani R,et aL Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients[J]. Diabetes Care, 2007, 30(5): 1212- 1218. 被引量:1
  • 6Ferreiral VS, Pemambucol RB, Lopesl EP, et al. Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus[J]. Arq Bras Endocrinol Metab, 2010, 54(4): 362-368. 被引量:1
  • 7郭琳,李强,于萍,等.2型糖尿病合并非酒精性脂肪性肝病患者血浆脂肪细胞特异性脂肪酸结合蛋白水平的分析[J].华州医学,2011,26(6):815-818. 被引量:1
  • 8Schernthaner G, Forst T, Gulba D, et al. Challenge in diabetes therapy: effects of glitazones beyond blood glucose control[J]. Dtseh Med Woehenschr, 2009, 8(4): 949-954. 被引量:1
  • 9Asehe CV, McAdam-Marx C, Shane-McWhorter L, et al. Association between oral antidiabetic use adverse events and outcomes in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2008, 10(8): 638-645. 被引量:1
  • 10Benton CR, Holloway GP, Campbell SE, et al. Rosiglitazone increases fatty acid oxidation and fatty acid transloease (FAT/CD36) but not carnitine palmitoyltransferase I in rat muscle mitochondria [J]. Physiol, 2008, 15(6): 1755-1766. 被引量:1

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部